Article Text

other Versions

Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved
  1. Liam Bourke1,
  2. Timothy J A Chico2,3,
  3. Peter C Albertsen4,
  4. Freddie C Hamdy5,
  5. Derek J Rosario6
  1. 1Department of Primary Care and Public Health, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
  2. 2NIHR Cardiovascular Biomedical Research Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Herries Road, Sheffield, UK
  3. 3Department of Cardiovascular Sciences, University of Sheffield, Sheffield, UK
  4. 4Department of Surgery, University of Connecticut Health Centre, Farmington, Connecticut, USA
  5. 5Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
  6. 6Academic Urology Unit, Department of Urology, School of Medicine, University of Sheffield, Royal Hallamshire hospital, Sheffield UK
  1. Correspondence to Derek J Rosario, Academic Urology Unit, K Floor, Department of Oncology, Royal Hallamshire Hospital, Glossop Road, University of Sheffield, Sheffield S11 7FE, UK; d.j.rosario{at}


Prostate cancer is a major and increasing public health burden. Androgen suppression therapy (AST) for prostate cancer provides well-established benefits in advanced stages of the disease. Unfortunately, mounting evidence suggests an association between AST and increased risk of cardiovascular disease (CVD). In this viewpoint, the authors seek to raise awareness of an underappreciated problem, summarise the evidence linking AST and CVD risk, and highlight important research questions that need to be addressed. Given the lack of a clear evidence base with which to dictate, the authors discuss possible management options and how these might be integrated into existing care pathways.

  • Cardiovascular diseases
  • prostatic neoplasms
  • androgens
  • risk factors
  • lifestyle
  • statins
  • public health
  • clinical trials
  • vascular biology
  • angiography

Statistics from


  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.